{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:35:01Z","timestamp":1789907701098,"version":"4.0.1"},"reference-count":50,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008065","name":"Georgia Research Alliance","doi-asserted-by":"publisher","award":["endowment"],"award-info":[{"award-number":["endowment"]}],"id":[{"id":"10.13039\/100008065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Influenza can cause respiratory infections, leading to significant morbidity and mortality in humans. While current influenza vaccines offer varying levels of protection, there remains a pressing need for effective antiviral drugs to supplement vaccine efforts. Currently, the FDA-approved antiviral drugs for influenza include oseltamivir, zanamivir, peramivir, and baloxavir marboxil. These antivirals primarily target the virus, making them vulnerable to drug resistance. In this study, we evaluated the efficacy of the neuraminidase inhibitor, oseltamivir, against probenecid, which targets the host cells and is less likely to engender resistance. Our results show that probenecid has superior antiviral efficacy compared to oseltamivir in both in vitro replication assays and in vivo mouse models of influenza infection.<\/jats:p>","DOI":"10.3390\/v15122366","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T07:44:42Z","timestamp":1701330282000},"page":"2366","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antiviral Activity of Probenecid and Oseltamivir on Influenza Virus Replication"],"prefix":"10.3390","volume":"15","author":[{"given":"Jackelyn","family":"Murray","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2820-5983","authenticated-orcid":false,"given":"David E.","family":"Martin","sequence":"additional","affiliation":[{"name":"TrippBio, Inc., Jacksonville, FL 32256, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred D.","family":"Sancilio","sequence":"additional","affiliation":[{"name":"TrippBio, Inc., Jacksonville, FL 32256, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-9956","authenticated-orcid":false,"given":"Ralph A.","family":"Tripp","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA"},{"name":"TrippBio, Inc., Jacksonville, FL 32256, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"ref_1","first-page":"459","article-title":"Antiviral effects of inhibiting host gene expression","volume":"386","author":"Tripp","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_2","first-page":"193","article-title":"Host gene expression and respiratory syncytial virus infection","volume":"372","author":"Tripp","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/ph6020124","article-title":"siRNA Genome Screening Approaches to Therapeutic Drug Repositioning","volume":"6","author":"Perwitasari","year":"2013","journal-title":"Pharmaceuticals"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1096\/fj.11-193466","article-title":"Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens","volume":"26","author":"Meliopoulos","year":"2012","journal-title":"FASEB J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-60327-295-7_4","article-title":"Therapeutic applications of RNAi for silencing virus replication","volume":"555","author":"Tripp","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tripp, R.A., and Martin, D.E. (2022). Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication. Viruses, 14.","DOI":"10.3390\/v14030612"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/AAC.01532-12","article-title":"Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy","volume":"57","author":"Perwitasari","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1152\/physrev.00025.2013","article-title":"The organic anion transporter (OAT) family: A systems biology perspective","volume":"95","author":"Nigam","year":"2015","journal-title":"Physiol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd4626","article-title":"SLC transporters as therapeutic targets: Emerging opportunities","volume":"14","author":"Lin","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Murray, J., Bergeron, H.C., Jones, L.P., Reener, Z.B., Martin, D.E., Sancilio, F.D., and Tripp, R.A. (2022). Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication. Viruses, 14.","DOI":"10.21203\/rs.3.rs-1280404\/v1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"18085","DOI":"10.1038\/s41598-021-97658-w","article-title":"Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro","volume":"11","author":"Murray","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Martin, D.E., Pandey, N., Chavda, P., Singh, G., Sutariya, R., Sancilio, F., and Tripp, R.A. (2023). Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19. Viruses, 15.","DOI":"10.3390\/v15071508"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e00826-19","DOI":"10.1128\/mBio.00826-19","article-title":"Comparative Loss-of-Function Screens Reveal ABCE1 as an Essential Cellular Host Factor for Efficient Translation of Paramyxoviridae and Pneumoviridae","volume":"10","author":"Anderson","year":"2019","journal-title":"mBio"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1074\/mcp.M114.044107","article-title":"New host factors important for respiratory syncytial virus (RSV) replication revealed by a novel microfluidics screen for interactors of matrix (M) protein","volume":"14","author":"Kipper","year":"2015","journal-title":"Mol. Cell. Proteom."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1128\/JVI.01625-07","article-title":"Viral and host factors in human respiratory syncytial virus pathogenesis","volume":"82","author":"Collins","year":"2008","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40124-013-0019-3","article-title":"Host and Viral Factors in Respiratory Syncytial Virus Infection","volume":"1","author":"Mastrangelo","year":"2013","journal-title":"Curr. Pediatr. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1574-6976.2006.00025.x","article-title":"Central role of the respiratory syncytial virus matrix protein in infection","volume":"30","author":"Ghildyal","year":"2006","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbrc.2017.01.005","article-title":"c-Jun N-terminal kinase activity is required for efficient respiratory syncytial virus production","volume":"483","author":"Caly","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Chen, J., Ye, C., Wan, C., Li, G., Peng, L., Peng, Y., and Fang, R. (2021). The Roles of c-Jun N-Terminal Kinase (JNK) in Infectious Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179640"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1194\/jlr.M088880","article-title":"Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid","volume":"60","author":"Won","year":"2019","journal-title":"J. Lipid Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1128\/MCB.00297-06","article-title":"Mitogen-activated protein kinase-mediated disruption of enhancer-promoter communication inhibits hepatocyte nuclear factor 4alpha expression","volume":"26","author":"Hatzis","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hammouda, M.B., Ford, A.E., Liu, Y., and Zhang, J.Y. (2020). The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer. Cells, 9.","DOI":"10.3390\/cells9040857"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"C761","DOI":"10.1152\/ajpcell.00227.2008","article-title":"Probenecid, a gout remedy, inhibits pannexin 1 channels","volume":"295","author":"Silverman","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.immuni.2021.06.014","article-title":"Pannexin 1 channels facilitate communication between T cells to restrict the severity of airway inflammation","volume":"54","author":"Medina","year":"2021","journal-title":"Immunity"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1111\/bph.14787","article-title":"Repurposing drugs targeting the P2X7 receptor to limit hyperinflammation and disease during influenza virus infection","volume":"176","author":"Rosli","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ijmm.2014.05.002","article-title":"Probenecid reduces infection and inflammation in acute Pseudomonas aeruginosa pneumonia","volume":"304","author":"Wonnenberg","year":"2014","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13596535211067598","DOI":"10.1177\/13596535211067598","article-title":"Discovery and development of oseltamivir at Gilead Sciences","volume":"27","author":"Schmitz","year":"2022","journal-title":"Antivir. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"ii5","DOI":"10.1093\/jac\/dkq015","article-title":"Pharmacokinetics of oseltamivir: An oral antiviral for the treatment and prophylaxis of influenza in diverse populations","volume":"65","author":"Davies","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cid\/ciy874","article-title":"Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1517\/13543784.7.2.149","article-title":"Development of antivirals against influenza","volume":"7","author":"Cianci","year":"1998","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Paradis, E.G., Pinilla, L.T., Holder, B.P., Abed, Y., Boivin, G., and Beauchemin, C.A. (2015). Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126115"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jiac.2017.06.001","article-title":"In vitro neuraminidase inhibitory concentration (IC(50)) of four neuraminidase inhibitors in the Japanese 2015-16 season: Comparison with the 2010\u201311 to 2014\u201315 seasons","volume":"23","author":"Ikematsu","year":"2017","journal-title":"J. Infect. Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1128\/AAC.46.12.3809-3816.2002","article-title":"Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1089\/adt.2015.0003.drrr","article-title":"Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication","volume":"13","author":"Perwitasari","year":"2015","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10651","DOI":"10.1128\/JVI.07244-11","article-title":"The H275Y neuraminidase mutation of the pandemic A\/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets","volume":"86","author":"Pinilla","year":"2012","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Farrukee, R., Tai, C.M.-K., Oh, D.Y., Anderson, D.E., Gunalan, V., Hibberd, M., Lau, G.Y.-F., Barr, I.G., von Messling, V., and Maurer-Stroh, S. (2020). Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008592"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chua, S.C.J.H., Tan, H.Q., Engelberg, D., and Lim, L.H.K. (2019). Alternative Experimental Models for Studying Influenza Proteins, Host\u2013Virus Interactions and Anti-Influenza Drugs. Pharmaceuticals, 12.","DOI":"10.3390\/ph12040147"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"15109","DOI":"10.1074\/jbc.M111.328070","article-title":"Influenza A virus neuraminidase protein enhances cell survival through interaction with carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) protein","volume":"287","author":"Gaur","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dki018","article-title":"Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic","volume":"55","author":"Ward","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1750-2659.2011.00235.x","article-title":"Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung","volume":"5","author":"Wong","year":"2011","journal-title":"Influ. Other Respir. Viruses"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1128\/AAC.01667-08","article-title":"Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model","volume":"53","author":"Govorkova","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd2175","article-title":"Antiviral agents active against influenza A viruses","volume":"5","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/cid\/cix1040","article-title":"Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials","volume":"66","author":"Malosh","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hanula, R., Bortolussi-Courval, \u00c9., Mendel, A., Ward, B.J., Lee, T.C., and McDonald, E.G. (2023). Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients with Influenza: A Systematic Review and Meta-analysis. JAMA Intern. Med.","DOI":"10.1001\/jamainternmed.2023.0699"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1086\/650458","article-title":"Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus","volume":"50","author":"Ng","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4062\/biomolther.2019.047","article-title":"Inhibitory Effect of Probenecid on Osteoclast Formation via JNK, ROS and COX-2","volume":"28","author":"Cheng","year":"2020","journal-title":"Biomol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1128\/MCB.25.9.3784-3792.2005","article-title":"Selective regulation of c-jun gene expression by mitogen-activated protein kinases via the 12-o-tetradecanoylphorbol-13-acetate- responsive element and myocyte enhancer factor 2 binding sites","volume":"25","author":"Kayahara","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1093\/emboj\/cdg364","article-title":"JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun","volume":"22","author":"Weiss","year":"2003","journal-title":"EMBO J."},{"key":"ref_49","first-page":"87","article-title":"Hepatocyte nuclear factor 4alpha regulates megalin expression in proximal tubular cells","volume":"17","author":"Sasaki","year":"2019","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1124\/mol.106.025494","article-title":"Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1alpha\/beta and DNA methylation","volume":"70","author":"Kikuchi","year":"2006","journal-title":"Mol. Pharmacol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2366\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:34:57Z","timestamp":1760132097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/12\/2366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["v15122366"],"URL":"https:\/\/doi.org\/10.3390\/v15122366","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}